Q1 Progress and Q2 Outlook

Dear Viska Investors and Supporters,

As we step into 2026 Viska Bio is operating with a clear sense of purpose. 2025 was a year of foundational validation for our nanobody-enzyme fusion protein platform. In Q1 of this year, we moved into execution mode.

Our goal is clear: transitioning from a discovery-stage pioneer to a development-stage organization. With the support of our partners at LabCentral and our dedicated investors, we are making the necessary strides to bring a new class of immunotherapy to patients.  

As we make progress, our board, team, and advisors feel a renewed clarity that we made the right choice last year to focus on Glioblastoma as our first cancer indication. The need is urgent, and Viska’s cure is promising. And, it was gratifying to hear enthusiastically received feedback from industry colleagues who attended our talk at the Glioblastoma Drug Development Summit in late February.

Check out the rest of our newsletter here.

Warm regards,

Eric